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blocking antibody. These data support that MR activation in human
endothelial cells promotes ICAM-1-mediated leukocyte-EC adhesion,
an important step in early atherosclerosis lesion formation. To further
explore the mechanisms for MR-mediated EC activation, we now
demonstrate that MR activation up-regulates VCAM-1 and E-selectin
mRNA expression (2 and 3.5 fold respectively), whereas P-selectin is
not regulated by MR. We also further explored the mechanism of MR-
mediated regulation of endothelial ICAM-1 expression. In transient
transfection experiments performed in HUVEC, we have shown that
aldosterone is able to activate (2 fold) a 3 Kb promoter region
upstream the transcription start site of human ICAM-1 gene. Co-
incubation with spironolactone was able to inhibit the effect of
aldosterone, conﬁrming the presence of elements responsive to
signaling pathway(s) activated by MR. In order to localize and
characterize MR responsive cis-element(s) and the corresponding
transcription factor(s) binding to this regulatory region, ﬁve 5′-
deletion constructs of ICAM-1 promoter were subcloned in a vector
upstream of the luciferase gene. Data of transcriptional activity
showed the presence of regulatory element(s) required for ICAM-1
expression via MR in the promoter region between nt-872 and -1141.
Bioinformatics analysis of this region revealed the presence of four
different highly conserved regulatory elements: three SP1 binding
sites, one NF-κB binding site, one AP1 binding site and one GRE/MRE.
The role of these transcription factors in MR-mediated regulation of
ICAM-1 expression was investigated using c-JUN and IKBα dominant
negative constructs. Blocking of either c-Jun or NF-κB pathway
resulted in a marked reduction of the aldosterone effect on ICAM-1
promoter activity, suggesting the involvement of these transcription
factors. These studies explore the molecular mechanism for the pro-
inﬂammatory effects of MR activation in the vasculature that may
contribute to explain the protective effects of MR antagonists in
clinical trials. Moreover to better understand the crosstalk between
MR activation and ICAM1 in the development of atherosclerosis
lesions, we developed a mouse model double KO for ApoE and ICAM1,
where we are currently studying the pro-atherogenic effects of
aldosterone.
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Statins are the most commonly prescribed drugs to treat lipid
disorders and reduce cardiometabolic risk. However, the use of
natural compounds may represent a valid support for statin-
intolerant patients. We aimed to assess the effect of bergamot-
derived polyphenolic fraction (BPF) in modulating serum cholesterol
and biomarkers of vascular oxidative stress in patients with mixed
hyperlipidemia either untreated or treated with rosuvastatin.
A prospective, open-label, parallel group, placebo-controlled
study on 77 patients with elevated serum LDL-C and triglycerides
was designed. Patients were randomly assigned to a control group
receiving placebo (n = 15), two groups receiving orally rosuvastatin
(10 and 20 mg/daily for 30 days n = 16 for each group), a group
receiving BPF alone orally (1000 mg/daily for 30 days; n = 15) and a
group receiving BPF (1000 mg/daily given orally) plus rosuvastatin
(10 mg/daily for 30 days; n = 15).
Both doses of rosuvastatin and BPF reduced total cholesterol, LDL-
C, the LDL-C/HDL-C ratio and urinary mevalonate in hyperlipidemic
patients, compared to control group. The cholesterol lowering effect
was accompanied by reductions of malondialdehyde, oxyLDL recep-
tor LOX-1 and phosphoPKB, which are all biomarkers of oxidative
vascular damage, in peripheral polymorphonuclear cells.
Addition of BPF to rosuvastatin signiﬁcantly enhanced
rosuvastatin-induced effect on serum lipemic proﬁle compared to
rosuvastatin alone, an effect associated to signiﬁcant reductions of
biomarkers used for detecting oxidative vascular damage, suggesting
a multiaction synergistic potential for BPF in statin-taking patients.
BPF may be an alternative therapeutic strategy for hyperlipidemia in
patients with statin-induced side effects.
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The occurrence of Metabolic Syndrome (MS) represents an
independent risk factor for developing cardiovascular disease states
in patients suffering from type 2 diabetes mellitus. Moreover, both
the size of LDL particles and liver dysfunction identiﬁed as non-
alcoholic fatty liver disease (NAFLD) represent important biomarkers
for the development of cardiometabolic risk in patients with MS. We
studied the effect of bergamot polyphenolic fraction (BPF) in patients
with MS and NAFLD. 107 patients were enrolled at the San Raffaele
IRCCS (Rome). All of them showed ultrasonograﬁc evidences of
NAFLD and at least three out of ﬁve previous identiﬁed criteria for
the diagnosis of MS. Patients were divided into two groups: one
receiving placebo and the second receiving BPF 650 mg twice a day
for 120 consecutive days. In the group receiving BPF 650 mg twice a
day, a signiﬁcant reduction of fasting plasma glucose, serum LDL
cholesterol and triglycerides alongside with an increase of HDL
cholesterol was found. This effect was accompanied by a signiﬁcant
reduction of both ultrasonographic and metabolic biomarkers of
NAFLD as well as by a decrease of small dense LDL particles.
Overall, our data show that bergamot-deriving polyphenolic
fraction given in patients with MS and NAFLD, leads to concomitant
amelioration of the lipemic and glycemic serum proﬁles and to
substantial reduction of liver steatosis. This effect, alongside with a
reduction of pro-atherogenic small dense LDL and enhancement of
anti-atherogenic high dense HDL, shed new light on the potential use
of bergamot-extract for reducing cardiometabolic risk in patients
with MS.
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